Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells The findings expand Telomir-1's oncology ...
Telomir Pharmaceuticals (NASDAQ:TELO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate ...
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical biotechnology company ...
-SEC Filing
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology com...
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expan...
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighti...
